Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Date:2/24/2009

AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008.

    Highlights

    - Extra clinical trial in LPL deficiency causes a delay of the announced
      filing date for lead product GlyberaTM which is now expected H2 2009
    - Positive clinical data on GlyberaTM
    - CEO Ronald Lorijn resigned for personal reasons
    - Start of clinical multicenter Hemophilia B trial in 2009
    - Start development of treatments for Duchenne Muscular Dystrophy and
      Parkinson's disease
    - Scale up of unique and proprietary production platform to fully support
      worldwide commercial supply for current products
    - Independent supervisory board with three new members bringing extensive
      knowledge and experience.
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 34.2 million at December 31, 2008

Results comparison

AMT's operating loss increased to EUR 18.8 million for 2008, from EUR 14.7 million for 2007. The difference is primarily due to the increase of research & development costs to EUR 13.1 million, from EUR 9.8 million in 2007. This increase is particularly related to the development work on the company's lead product, GlyberaTM, increased staffing for this and other programs and an increase in research collaborations. General and administrative costs increased to EUR 5.9 million, from EUR 5.0 million in 2007, primarily as a result of increased employee costs and increased advisor's fees. The net loss for 2008 was EUR 16.9 million, as compared to a net loss of EUR 14.9 million for 2007. As of December 31, 2008, AMT had cash and cash equivalents of EUR 34.2 million, compared to EUR 51.3 million at December 31, 2007. The cash burn for the year amounted to EURO 17.2 million which i
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
4. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 , ... , , , Microorganism , ... Cell type , Bacteria, gram negative, ...
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. ... , , , , , , ... , , Cell type , ...
... Eppendorf's Perfectprep Plasmid , Mini Kit , ... , James Griffith and Kim Vollmer , ... Vollmer, Brinkmann Instruments, Biosytems Application Lab, Westbury, , NY , , ... , Cosmids are commonly used vectors in the lab, ...
Cached Biology Technology:Actinomyces viscosus 2Actinobacillus pleuropneumoniae 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 3Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 4Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 5
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... Pregnant women taking prenatal supplements may not be getting enough ... Child & Family Research Institute at BC Children,s Hospital that ... . The study found that while almost 80 per ... many were vitamin D insufficient. Insufficient means that blood levels ...
... (Santa Barbara, Calif.) Viruses fill the ocean and ... microbiology, according to a professor of biology at UC ... professor with UCSB,s Department of Ecology, Evolution, and Marine ... marine viruses published this week by the International ...
... is a well-oiled machine with tiny protein motors hauling chromosomes, ... motors are responsible for a variety of critical transport jobs, ... put themselves into "energy save mode" to conserve cellular fuel ... cell, and when. A new study from ...
Cached Biology News:Pregnant women in Vancouver may not be getting enough vitamin D 2Decade-long study reveals recurring patterns of viruses in the open ocean 2Decade-long study reveals recurring patterns of viruses in the open ocean 3Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 2Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 3
Request Info...
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Biology Products: